Description
Title: Results of a Salvage Regimen of Six High-Dose Cytarabine Doses for Patients with Relapsed/Refractory Acute Myeloid Leukemia
Abstract: Relapsed/refractory acute myeloid leukemia (RR-AML) has a poor prognosis and allogeneic hematopoietic cell transplantation is necessary for long-term disease-free survival (allo-HCT). Regarding the best course of treatment to achieve remission before allo-HCT, there is a paucity of information. Induction therapy has previously used a single agent high-dose cytarabine (10–12 doses administered every 12 hours). HiDAC-6, a six-dose consolidation regimen that is frequently used, has never been studied as an induction therapy. We present a retrospective analysis of 26 RR-AML patients who received six doses of the single agent cytarabine, 3 g/m2, intravenously every 12 hours on days 1, 3, and 5. (HiDAC-6). The median follow-up for patients who survived was 10.4 months (range 1.6–112.2months). 62% of the patients experienced complete remission (54% CR and 8% CRi). The median overall survival (OS) was 9.6 months, the event-free survival (EFS) was 4.7 months, and the relapse-free survival (RFS) was 22.3 months on average (range: 0.7 to 112 months) (range 1–112 months). 35 percent of patients were able to move on to allo-HCT after that. Neutropenia (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%), among other toxicities, were all caused by the treatment. This is the first study to show HiDAC-6 as an active treatment option for younger RR-AML patients that can safely and effectively act as a bridge to allo-HCT.Relapsed/refractory acute myeloid leukemia (RR-AML) has a poor prognosis and allogeneic hematopoietic cell transplantation is necessary for long-term disease-free survival (allo-HCT). Regarding the best course of treatment to achieve remission before allo-HCT, there is a paucity of information. Induction therapy has previously used a single agent high-dose cytarabine (10–12 doses administered every 12 hours). HiDAC-6, a six-dose consolidation regimen that is frequently used, has never been studied as an induction therapy. We present a retrospective analysis of 26 RR-AML patients who received six doses of the single agent cytarabine, 3 g/m2, intravenously every 12 hours on days 1, 3, and 5. (HiDAC-6). The median follow-up for patients who survived was 10.4 months (range 1.6–112.2months). 62% of the patients experienced complete remission (54% CR and 8% CRi). The median overall survival (OS) was 9.6 months, the event-free survival (EFS) was 4.7 months, and the relapse-free survival (RFS) was 22.3 months on average (range: 0.7 to 112 months) (range 1–112 months). 35 percent of patients were able to move on to allo-HCT after that. Neutropenia (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%), among other toxicities, were all caused by the treatment. This is the first study to show HiDAC-6 as an active treatment option for younger RR-AML patients that can safely and effectively act as a bridge to allo-HCT.Relapsed/refractory acute myeloid leukemia (RR-AML) has a poor prognosis and allogeneic hematopoietic cell transplantation is necessary for long-term disease-free survival (allo-HCT). Regarding the best course of treatment to achieve remission before allo-HCT, there is a paucity of information. Induction therapy has previously used a single agent high-dose cytarabine (10–12 doses administered every 12 hours). HiDAC-6, a six-dose consolidation regimen that is frequently used, has never been studied as an induction therapy. We present a retrospective analysis of 26 RR-AML patients who received six doses of the single agent cytarabine, 3 g/m2, intravenously every 12 hours on days 1, 3, and 5. (HiDAC-6). The median follow-up for patients who survived was 10.4 months (range 1.6–112.2months). 62% of the patients experienced complete remission (54% CR and 8% CRi). The median overall survival (OS) was 9.6 months, the event-free survival (EFS) was 4.7 months, and the relapse-free survival (RFS) was 22.3 months on average (range: 0.7 to 112 months) (range 1–112 months). 35 percent of patients were able to move on to allo-HCT after that. Neutropenia (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%), among other toxicities, were all caused by the treatment. This is the first study to show HiDAC-6 as an active treatment option for younger RR-AML patients that can safely and effectively act as a bridge to allo-HCT.
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Medicine
Sub Category: Hematology
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.